

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2018**

Commission File Number: **001-32001**

**Aptose Biosciences Inc.**

(Translation of registrant's name into English)

251 Consumers Road, Suite 1105

Toronto, ON

M2J 4R3

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [  ] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

On June 5, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[\(c\) Exhibit 99.1. Press release dated June 5, 2018](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Aptose Biosciences Inc.**  
(Registrant)

Date: June 5, 2018

/s/ Gregory K. Chow  
Gregory K. Chow  
Senior Vice President and Chief Financial Officer

## Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, June 05, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the voting results from the Company’s annual meeting of shareholders held today, June 5, 2018 (the “Meeting”). A total of 27.75% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.

The Company is pleased to announce that all of the nominees listed in the management proxy circular dated April 26, 2018 were elected as directors. Each of the directors was elected with greater than 99% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote are detailed below:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Dr. Denis Burger	8,572,807	99.44	48,328	0.56
Ms. Caroline Loewy	8,595,118	99.70	26,017	0.30
Dr. Erich Platzer	8,595,262	99.70	25,873	0.30
Dr. William Rice	8,595,955	99.71	25,180	0.29
Dr. Mark Vincent	8,592,549	99.67	28,586	0.33
Warren Whitehead	8,592,841	99.67	28,294	0.33

Aptose shareholders also voted to re-appoint KPMG LLP as auditor of the Company.

In addition, a resolution for the approval of all unallocated options under the share option plan of the Company, and a resolution for the approval of all unallocated awards under the Company’s stock incentive plan were approved by the shareholders at the Meeting.

Please refer to the Company’s management proxy circular available on SEDAR at [www.sedar.com](http://www.sedar.com) or EDGAR <https://www.sec.gov/edgar.shtml> for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR and EDGAR.

### About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit [www.apptose.com](http://www.apptose.com).

For further information, please contact:

#### Aptose Biosciences

Greg Chow, Chief Financial Officer  
647-479-9828  
[gchow@aptose.com](mailto:gchow@aptose.com)

#### SMP Communications

Susan Pietropaolo  
201-923-2049  
[susan@smpcommunications.com](mailto:susan@smpcommunications.com)

#### LifeSci Advisors

Michael Wood, Managing Director  
646-597-6983  
[mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)